Valpromide is a poor inhibitor of the cytosolic epoxide hydrolase.
The effect of the antiepileptics valpromide and sodium valproate on the cytosolic epoxide hydrolase was studied in human fetal liver, kidneys and adrenals and from human adult liver and kidneys. Trans-stilbene oxide was used as substrate. Valpromide (10 mM) lowered the activity of the epoxide hydrolase to one half of the control in all organs studied. Sodium valproate (10 mM) was less powerful as an inhibitor than valpromide; however, it exerted a significant inhibition in all tissues studied.
Pacifici
G M
GM
Department of General Pathology, University of Pisa, Italy.
Temellini
A
A
Giuliani
L
L
Rane
A
A
Thomas
H
H
Oesch
F
F
D000927:Anticonvulsants / Q000494:pharmacology*; D003600:Cytosol / Q000201:enzymology*; D004851:Epoxide Hydrolases / Q000037:antagonists & inhibitors*; D005260:Female; D005333:Fetus / Q000378:metabolism; D006801:Humans; D066298:In Vitro Techniques; D008099:Liver / Q000201:enzymology; D011247:Pregnancy; D013267:Stilbenes / Q000378:metabolism; D014635:Valproic Acid / Q000031:analogs & derivatives / Q000494:pharmacology*
D000927:Anticonvulsants; D013267:Stilbenes; D014635:Valproic Acid; D004851:Epoxide Hydrolases; C004651:dipropylacetamide